Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer

被引:83
作者
Miyakita, H [1 ]
Tokunaga, M
Onda, H
Usui, Y
Kinoshita, H
Kawamura, N
Yasuda, S
机构
[1] Tokai Univ, Sch Med, Dept Urol, Kanagawa 2591193, Japan
[2] Tokai Univ, Sch Med, Dept Surg, Kanagawa 2591193, Japan
关键词
FDG-PET; GLUT-1; renal cell carcinoma;
D O I
10.1046/j.1442-2042.2002.00416.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications. Glucose transporter 1 (GLUT-1) is recognized as a major early marker of cellular malignant transformation. The aims of this study were to assess whether FDG-PET is a useful diagnostic tool for renal cell carcinoma and to compare the pathologic characteristics. Methods: Nineteen consecutive patients who had renal cell carcinoma were examined using FDG-PET preoperatively. The results of PET were then compared to the histology obtained after radical surgery and the immunoreactivity of GLUT-1 was also studied. Results: Pathologic examination confirmed that all 19 patients suffered from renal cell carcinoma. Increased FDG uptake was found in six of the 19 patients (31.5%). The immunohistochemical examination of GLUT-1 in renal cell carcinoma produced different results in each patient. There was no correlation with GLUT-1 immunoreactivity and FDG-PET positivity. Conclusion: These results suggest that FDG-PET may not be a useful diagnostic tool for renal cell carcinoma.
引用
收藏
页码:15 / 18
页数:4
相关论文
共 11 条
[1]  
[Anonymous], 1996, J NUCL MED
[2]  
Bachor R, 1996, UROLOGE A, V35, P146
[3]  
HOH CK, 1996, J NUCL MED, V37, P141
[4]   FACILITATIVE GLUCOSE TRANSPORTERS [J].
MUECKLER, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 219 (03) :713-725
[5]  
Oshida M, 1998, CANCER, V82, P2227, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO
[6]  
2-W
[7]  
PHELPS ME, 1986, POSITRON EMISSION TO
[8]  
STAUSS LG, 1991, J NUCL MED, V32, P623
[9]   IMAGING OF RENAL-CANCER USING POSITRON EMISSION TOMOGRAPHY WITH 2-DEOXY-2(18F)-FLUORO-D-GLUCOSE - PILOT ANIMAL AND HUMAN STUDIES [J].
WAHL, RL ;
HARNEY, J ;
HUTCHINS, G ;
GROSSMAN, HB .
JOURNAL OF UROLOGY, 1991, 146 (06) :1470-1474
[10]  
Wahl RL., 1994, NUCL MED CLIN DIAGNO, V2, P801